Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer.

被引：1
|
作者：
Srinivas, Sandy
Narayanan, Sujata
Harshman, Lauren Christine
Pachynski, Russell Kent
Lam, Anthony P.
Fan, Alice C.
Poushnejad, Shermeen
Haas, Denise
Vaishampayan, Ulka N.
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Stanford, CA 94305 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Washington Univ, Sch Med, St Louis, MO USA
[5] Stanford Canc Inst, Stanford, CA USA
[6] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.294
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
294
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer
    Narayanan, Sujata
    Lam, Anthony
    Vaishampayan, Ulka
    Harshman, Lauren
    Fan, Alice
    Pachynski, Russell
    Poushnejad, Shermeen
    Haas, Denise
    Li, Shufeng
    Srinivas, Sandy
    CLINICAL GENITOURINARY CANCER, 2016, 14 (05) : 432 - 437
  • [2] Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer (UC).
    Srinivas, Sandy
    Narayanan, Sujata
    Harshman, Lauren Christine
    Lam, Anthony P.
    Vaishampayan, Ulka N.
    Haas, Denise
    Poushnejad, Shermeen
    Pachynski, Russell
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [3] Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer
    Jones, Robert J.
    Hussain, Syed A.
    Protheroe, Andrew S.
    Birtle, Alison
    Chakraborti, Prabir
    Huddart, Robert A.
    Jagdev, Satinder
    Bahl, Amit
    Stockdale, Andrew
    Sundar, Santhanam
    Crabb, Simon J.
    Dixon-Hughes, Judith
    Alexander, Laura
    Morris, Anna
    Kelly, Caroline
    Stobo, Jon
    Paul, James
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) : 1770 - +
  • [4] Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer
    Horiguchi, Miki
    Uno, Hajime
    Wei, Lee-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3373 - +
  • [5] Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer Reply
    Paul, James
    Kelly, Caroline
    Stobo, Jon
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29)
  • [6] Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer.
    Van der Burg, ME
    Vergote, I
    Burger, CW
    van der Gaast, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 463S - 463S
  • [7] Design of an open label, randomized, phase II study of paclitaxel and panitumumab compared to paclitaxel alone in patients with relapsed or refractory urothelial cancer.
    Necchi, Andrea
    Mariani, Luigi
    Giannatempo, Patrizia
    Raggi, Daniele
    Calareso, Giuseppina
    Crippa, Flavio
    Togliardi, Elena
    Salvioni, Roberto
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Pazopanib versus paclitaxel in relapsed urothelial tumors: A randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive transitional cell carcinoma of the urothelium (PLUTO).
    Jones, Robert J.
    Chester, John D.
    Dixon-Hughes, Judith
    Alexander, Laura
    Bahl, Amit
    Hussain, Syed A.
    Birtie, Alison
    Jagdev, Satinder
    Morris, Anna
    Stobo, Jamie
    Bray, Caroline A.
    Paul, James
    Powies, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer
    Yamamoto, N
    Tsurutani, J
    Yoshimura, N
    Asai, G
    Moriyama, A
    Nakagawa, K
    Kudoh, S
    Takada, M
    Minato, Y
    Fukuoka, M
    ANTICANCER RESEARCH, 2006, 26 (1B) : 777 - 781
  • [10] A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer
    Friedland, DM
    Dakhil, S
    Hollen, C
    Gregurich, MA
    Asmar, L
    CANCER INVESTIGATION, 2004, 22 (03) : 374 - 382
12345